Effect of sodium thiosulfate on cisplatin removal after intra-arterial embolization with a lipiodol-platinum suspension for hepatocellular carcinoma

References

• Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, . Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:25–9.
   PubMed Web of Science ®Google Scholar
• Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, . Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;162:345–51.
   PubMedGoogle Scholar
• Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783–6.
   PubMed Web of Science ®Google Scholar
• Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999;10:793–8.
   Google Scholar
• Nishizaki T, Takenaka K, Yoshida K, Ikeda T, Sugimachi K. Influence of lipiodolization on a cirrhotic liver. J Surg Oncol 1995;58:263–8.
   Google Scholar
• Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, . A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194–203.
   PubMed Web of Science ®Google Scholar
• Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, . Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965–71.
   PubMed Web of Science ®Google Scholar
• Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586–94.
   PubMed Web of Science ®Google Scholar
• Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, . Effect of arterial administration of high molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983;19:1053–65.
   PubMedGoogle Scholar
• Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986;8:356–67.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, . In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmcol 1997;39: 493–7.
   PubMed Web of Science ®Google Scholar
• Dedon PC, Borch RF. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1988; 36:1955–64.
   Google Scholar
• Elferink F, Van der Vugh WJF, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem 1988;32:641–5.
   Google Scholar
• Iwamato Y, Kawano T, Uozumi J, Aoki K, Baba T. “Two-route chemotherapy” using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep 1984;68:1367–73.
   Google Scholar
• Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, . Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845–51.
   PubMed Web of Science ®Google Scholar
• Pfeifle CE, Howell SB, Felthouse RD, Woliver TBS, Andrews PA, Markman M, . High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985;3:237–44.
   PubMed Web of Science ®Google Scholar
• Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, The liver and portal hypertension. Philadelphia: Saunders; 1964. 49–51.
   Google Scholar
• Hermanek P, Sobin LH(International Union Against Cancer [UICC]), editors. TNM classification of malignant tumors. Fourth edition. Berlin: Springer Verlag; 1987. 53–5.
   Google Scholar
• Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konnno T, Miyauchi Y, . Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52:2193–200.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Nakagawa N, Miyawaki M, Bussaka H, Takahashi M, Fujimura N, . [Experimental study of hepatic arterial embolization therapy by various formulations of the anticancer agent lipiodol.] Nippon Acta Radiol 1985;45:1313–21(in Japanese).
   Google Scholar
• Kobayashi H, Hidaka H, Kajiya Y, Tanoue P, Inoue H, Ikeda K, . Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol 1986;27:139–47.
   Google Scholar
• Shimada Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T, . Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull 2005;28:1635–8.
   Google Scholar
• Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005;28: 1385–8.
   PubMed Web of Science ®Google Scholar
• Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426–31.
   PubMed Web of Science ®Google Scholar
• Abe R, Akiyoshi T, Koba F, Tsuji H, Baba T. ‘Two-route chemotherapy’ using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. Eur J Cancer Clin Oncol 1988;24: 1671–4.
   PubMedGoogle Scholar
• Markman M, D'Acquisto R, Iannotti N, Kris M, Hakes T, Bajorin D, . Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. J Cancer Res Clin Oncol 1991;117:151–5.
   Google Scholar
• Reichman B, Markman M, Hakes T, Jones W, Lewis JL Jr, Rubin S, . Phase II trial of highdose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. Gynecol Oncol 1991;43:159–63.
   Google Scholar
• Fukushima S, Kawaguchi T, Nishida M, Juni K, Yamashita Y, Takahashi M, . Selective anticancer effects of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumor. Cancer Res 1987;47:1930–4.
   PubMed Web of Science ®Google Scholar
• Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma: a phase II study. Cancer 1986;58:2386–8.
   PubMed Web of Science ®Google Scholar
• Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995; 377:649–52.
   PubMed Web of Science ®Google Scholar
• Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002;42:317–25.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, . In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 1997;39: 493–7.
   PubMed Web of Science ®Google Scholar
• Inoue M, Shimizu C, Shimizu H, Tanizawa O. Neutralizing effect of sodium thiosulfate on antitumor efficancy of cisplatin for human carcinoma xenografts in nude mice. Gynecol Oncol 1991;40:34–7.
   PubMed Web of Science ®Google Scholar
• Robbins KT, Kumar P, Wong FS. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 2000;22:87–93.
   Google Scholar